Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 7,644,610	$ 500,962
Accounts receivable, net	155,426	102,799
Inventory	49,319	37,776
Prepaid expenses and other assets	988,579	946,386
Total current assets	8,837,934	1,587,923
Property and equipment, net	1,116,360	299,910
Goodwill	9,178,477
Intellectual property and patents, net	1,674,283	1,206,011
In-process research and development	14,460,000
Prepaid expenses and other assets	33,825	232,407
Other assets	46,097	69,837
Total assets	35,346,976	3,396,088
Current liabilities:
Accounts payable	539,486	774,387
Accrued expenses	178,330	508,733
Loan payable	26,930	105,125
Notes payable, net	50,000	920,000
Convertible promissory notes, net	550,000	5,242,431
Derivative liability	344,625	617,628
Deferred revenue	318,083	383,275
Total current liabilities	2,007,454	8,551,579
License Fees	95,000
Contingent share considerations	23,152,000
Total liabilities	25,254,454	8,551,579
Commitments and Contingencies (see Note 15)
Stockholders' equity (deficit):
Common stock: $0.001 par value; authorized 75,000,000 shares; 36,487,051 shares and 26,784,019 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	36,488	26,785
Additional paid-in capital	58,357,584	23,424,737
Stock payable	3,643,225	645,575
Accumulated deficit	(51,944,775)	(29,269,000)
Total CURE Pharmaceutical Holding Corp stockholders equity (deficit)	10,092,522	(5,171,903)
Noncontrolling interest		16,412
Total stockholders' equity (deficit)	10,092,522	(5,155,491)
Total liabilities and stockholders' equity (deficit)	$ 35,346,976	$ 3,396,088